On May 29, ASCO’s CancerLinQ® announced that it launched a new platform for CancerLinQ Discovery®, its de-identified real-world cancer data product for researchers across the cancer community.
ALEXANDRIA, Va. — Positive results from two cohorts of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study provide real world evidence to support recent clinical trial data that demonstrate a role for olaparib (Lynparza) in the treatment of advanced prostate and pancreatic cancers with BRCA1/2 inactivating mutations.
ALEXANDRIA, Va. - Conquer Cancer, the ASCO Foundation, is honored to announce the recipients of its awards supporting researchers with projects spanning many areas in cancer care, including immunotherapy, lung, breast cancer, and palliative care. The awards will be given in conjunction with the virtual scientific program of the 2020 ASCO Annual Meeting.
ALEXANDRIA, Va. — In patients with cancer and COVID-19, cancer that is progressing was independently associated with an increased risk of death, according to an analysis of 928 patients. COVID-19 treatment with both hydroxychloroquine and azithromycin was also strongly associated with increased risk of death, according to data from the COVID-19 and Cancer Consortium (CCC19) registry. The registry contains data from patients who have tested positive for COVID-19 and around 40% of patients in the registry also have active cancer. The data will be presented as part of the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.
ALEXANDRIA, Va. — Among patients with lung and other thoracic cancers also diagnosed with COVID-19, prior use of chemotherapy — alone or in combination with other treatments — was associated with increased risk of death, according to an analysis to be presented as part of the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. The data come from the Thoracic cancERs international coVid 19 cOLlaboraTion (TERAVOLT) registry and are the most recent available.
ALEXANDRIA, Va. — Researchers have developed an algorithm to identify molecular targets and pair them with targeted therapies for relapsed pediatric cancers with a poor prognosis. In a recent study, this approach extended the time until disease progression by three months for a small group of pediatric patients with very high-priority targets. The study findings will be presented during the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.
ALEXANDRIA, Va. — In a small, phase II study of a very rare cancer that develops inside a woman’s uterus during or after pregnancy, treatment with avelumab (Bavencio) potentially cured 8 out of 15 women with cancer that was resistant to single-agent chemotherapy. This is the first trial exploring use of immunotherapy in patients with gestational trophoblastic tumors (GTT) and suggests that avelumab may be a new therapeutic option for these patients. The results will be presented during the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.
ALEXANDRIA, Va. — Treatment with avelumab combined with best supportive care following chemotherapy significantly extended overall survival compared with best supportive care alone in patients with advanced urothelial cancer in the JAVELIN Bladder 100 trial. The results of this study will be presented during the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.
ALEXANDRIA, Va. — Treatment with targeted therapy osimertinib (Tagrisso) following surgery for localized non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation significantly improved disease-free survival in a phase III study. Of patients with stage II-IIIA NSCLC who received osimertinib, 90% were alive at two years without the cancer recurring, compared with 44% who received a placebo. In stage II-IIIA patients, the risk of disease recurrence or death was reduced by 83% for patients treated with adjuvant osimertinib after surgery compared to placebo.
ALEXANDRIA, Va. — Front-line therapy with the immune checkpoint inhibitor pembrolizumab (Keytruda) doubled progression-free survival vs chemotherapy in patients with a type of advanced colorectal cancer that has a high number of mutations, which previous research suggests may have a poor prognosis for some patients. This is the first time pembrolizumab has been shown to benefit these patients when used as a front-line therapy. The findings come from an interim analysis of the phase III KEYNOTE-177 trial that will be presented during the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.
ASCO released the ASCO Special Report: A Guide to Cancer Care Delivery During the COVID-19 Pandemic, which provides detailed guidance to oncology practices on the immediate and short-term steps that could be taken to help protect the safety of patients and healthcare staff before resuming more routine care operations during the COVID-19 public health crisis.
ALEXANDRIA, Va. — Older people with cancer set to receive anti-cancer therapy had significant improvements in quality of life when comprehensive geriatric assessment and geriatrician-led management was integrated into their care plan. The prospective, randomized, open-label INTEGERATE trial, according to the study authors, is the first randomized clinical trial in geriatric oncology to show that an integrated approach involving geriatricians and oncologists working in partnership helped improve quality of life, and reduced hospital admissions and early discontinuation of treatment due to adverse events.
ALEXANDRIA, Va. — A videoconferencing intervention significantly reduced levels of anxiety and distress among “distance caregivers" who live more than an hour away from the patients with cancer they support, according to the results of a federally funded study.
ALEXANDRIA, Va. — States that adopted Medicaid expansion following passage of the Affordable Care Act (ACA) of 2010 saw greater decreases in cancer mortality rates than states that did not, according to the first nationwide study of its kind.
ALEXANDRIA, Va. — People who quit smoking at any time — even less than 2 years before a lung cancer diagnosis — improve their chances of survival after being diagnosed with the disease, according to the results of a large international study that will be presented during the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.